Discover and read the best of Twitter Threads about #CVPrev
Most recents (11)
Check out Top 10🔑points from the 🆕ACC/@American_Heart/@HFSA Guideline for the Management of #HeartFailure #CardioTwitter #ClinicalGuidelines #ACC22
🧵Key Points👇
🧵Key Points👇
1⃣ Guideline-directed medical therapy for #HeartFailure w/ reduced ejection fraction #HFrEF now incorporates four medication classes that include #SGLT2i. #ClinicalGuidelines 
2⃣ #SGLT2i have a Class of Recommendation 2a in #HFmrEF. Weaker recommendations (COR 2b) are made for ARNi, ACEi, ARB, MRA & beta blockers in this population. #ClinicalGuidelines
#ESCCongress #HOTLINE #cvPrev #STEPStudy
Can intensive tx ⬇️ CVD risk risk HTN, older 👴🧓
🫀Optimum BP remains uncertain in older pt: differing rec's worldwide
🫀🇨🇳 age 60-80y, 9624 pts RCT, >50% Home BP cuff provided
🫀Intensive 110-130 SBP vs 130-150: 26% benefit with int tx
Can intensive tx ⬇️ CVD risk risk HTN, older 👴🧓
🫀Optimum BP remains uncertain in older pt: differing rec's worldwide
🫀🇨🇳 age 60-80y, 9624 pts RCT, >50% Home BP cuff provided
🫀Intensive 110-130 SBP vs 130-150: 26% benefit with int tx
#ESCCongress #STEPStudy
🫀 No diff in afib, coronary revasc, Mortality but all other endpoints significant
🫀 Safe: Hypotension more common in Intensive arm but no great syncope
🫀 No subgroup diff
How low should we go? Lower!
@NEJM nejm.org/doi/full/10.10…
@Steph_Achenbach
🫀 No diff in afib, coronary revasc, Mortality but all other endpoints significant
🫀 Safe: Hypotension more common in Intensive arm but no great syncope
🫀 No subgroup diff
How low should we go? Lower!
@NEJM nejm.org/doi/full/10.10…
@Steph_Achenbach
#ESCCongress #STEPStudy
➡️Mean age 66 (75% below age of 70)
➡️ Most with well controlled BP at entry
Context of patient heterogenity
🫀Signif impact on CV events
🫀 Tx well tolerated & achieved! (SBP 126 Intensive)
🫀Is this SPRINT? BP achieved similar to STEP
➡️Mean age 66 (75% below age of 70)
➡️ Most with well controlled BP at entry
Context of patient heterogenity
🫀Signif impact on CV events
🫀 Tx well tolerated & achieved! (SBP 126 Intensive)
🫀Is this SPRINT? BP achieved similar to STEP
#ESCCongress #HOTLINE #IAMI
Does influenza vaccination improves outcomes in patients with recent MI?
💉 Flu assoc 🫀 death
💉 Vaccine=Class 1 ESC/AHA/ACC
💉8 countries, 4 Flu seasons RCT- double blind of AMI pt, 2571 pts: mostly male (>80%)
💉28% ⬇️ events with vaccine 🆚placebo
Does influenza vaccination improves outcomes in patients with recent MI?
💉 Flu assoc 🫀 death
💉 Vaccine=Class 1 ESC/AHA/ACC
💉8 countries, 4 Flu seasons RCT- double blind of AMI pt, 2571 pts: mostly male (>80%)
💉28% ⬇️ events with vaccine 🆚placebo
#ESCCongress #HOTLINE #IAMI
💉Safe, well tolerated
💉In patients with MI/high risk CAD benefit from influenza vaccination
💉Flu & CVD: 2 of the most common causes of 🏥
Vaccine ⬇️ risk of flu, all cause death and CV events now
High risk pt benefit from flu vaccine
#CVprev
💉Safe, well tolerated
💉In patients with MI/high risk CAD benefit from influenza vaccination
💉Flu & CVD: 2 of the most common causes of 🏥
Vaccine ⬇️ risk of flu, all cause death and CV events now
High risk pt benefit from flu vaccine
#CVprev
#ESCCongress #IAMI
💉Flu vaccine does ⬇️CV deaths but does not seem to ⬇️ acute CV events in post-AMI patients
💉Data clearly shows influenza vaccine is useful in high risk patients with CVD. Mechanism isn't clear but does that matter?
💉Vaccinate people after #AMI in 🏥!
💉Flu vaccine does ⬇️CV deaths but does not seem to ⬇️ acute CV events in post-AMI patients
💉Data clearly shows influenza vaccine is useful in high risk patients with CVD. Mechanism isn't clear but does that matter?
💉Vaccinate people after #AMI in 🏥!
#ESCCongress #HOTLINE #CardioTwitter #CVPrev
#SSaSS Salt Substitute and Stroke Study @georgeinstitute
🫀Included w/ prior stroke or poorly controlled BP
🫀Interventional: Salt subs
🫀 65y 50%💃 73% hx stroke
🫀3.3 SPB⬇️
🫀⬇️ stroke&CV events
🫀Salt subs is effective to ⬇️ stroke
#SSaSS Salt Substitute and Stroke Study @georgeinstitute
🫀Included w/ prior stroke or poorly controlled BP
🫀Interventional: Salt subs
🫀 65y 50%💃 73% hx stroke
🫀3.3 SPB⬇️
🫀⬇️ stroke&CV events
🫀Salt subs is effective to ⬇️ stroke
#ESCCongress #HOTLINE #CardioTwitter #CVPrev
#SSaSS
🫀Study could impact CVD health of the world
@NEJM Read here: bit.ly/3yuVqxU
Fantastic study!!!!!!! @ASPCardio @CardioSmart
#SSaSS
🫀Study could impact CVD health of the world
@NEJM Read here: bit.ly/3yuVqxU
Fantastic study!!!!!!! @ASPCardio @CardioSmart
💥Very Important study
💥High risk group- mean age 65, 3/4 with stroke, high salt intake (but typical in the world for many)
💥5000 MACE: Power enormous
💥3mmHg SBP ⬇️
⬇️ in stroke & mortality HUGE! Simple intervention
#ESCCongress @Steph_Achenbach
#CVPrev #cardiotwitter
💥High risk group- mean age 65, 3/4 with stroke, high salt intake (but typical in the world for many)
💥5000 MACE: Power enormous
💥3mmHg SBP ⬇️
⬇️ in stroke & mortality HUGE! Simple intervention
#ESCCongress @Steph_Achenbach
#CVPrev #cardiotwitter
#ESCCongress #HOTLINE #LOOP study #CVprev
Screening for #Afib with loop recorder to prevent stroke
🫀 Incl:age >/=70& 1+ RF; Excl:known Afib
🫀 ILR (Linq) vs Control: afib: tx with OAC
🫀1o: Time to stroke or systemic embolism: 64m F/U
🫀42%💃
💥 AF 32% ILR vs 12% Control w/ OAC
Screening for #Afib with loop recorder to prevent stroke
🫀 Incl:age >/=70& 1+ RF; Excl:known Afib
🫀 ILR (Linq) vs Control: afib: tx with OAC
🫀1o: Time to stroke or systemic embolism: 64m F/U
🫀42%💃
💥 AF 32% ILR vs 12% Control w/ OAC
#ESCCongress #HOTLINE #LOOP study #CVprev
Screening for #Afib with loop recorder to prevent stroke
🫀1o outcome:NS
🫀2o outcome NS
🫀 death from any cause NS
🩸 NS dif in Bleed
[Baseline SBP>157: benefit from ILR but hope they tx BP!]
💥Afib diagnosed but NS diff in any outcomes
Screening for #Afib with loop recorder to prevent stroke
🫀1o outcome:NS
🫀2o outcome NS
🫀 death from any cause NS
🩸 NS dif in Bleed
[Baseline SBP>157: benefit from ILR but hope they tx BP!]
💥Afib diagnosed but NS diff in any outcomes
Our #systematicreview and #metaanalysis on the association of #sepsis with long-term #CVD is out now in @yourICM ! Surviving sepsis was associated with ⬆️#cvMI, #heartfailure, and #stroke over 5+ years. Take-home points below. tinyurl.com/p5n634jy
1. Many studies have examined the risk of #CVD after #sepsis, but variable population and outcome selection has complicated generalizability. We estimated the risk of #cvMI, #heartfailure, #stroke, and composite #CVD after sepsis relative to hospital and population controls.
2. 12,649 citations identified, 27 (25 cohort, 2 case-crossover) studies included. Median of 4,289 (IQR 502–68,125) sepsis survivors and 18,399 (IQR 4,028–83,506) controls per study. We assessed cumulative incidence and relative risk of #CVD from 30 days to longest follow-up.
Women are not smaller men! #Atherosclerosis genesis, progression & sequelae different in women. Plaque erosion causing ACS more common in women. Women have unique #SDOH, are undertreated with #cvPrev therapies & #GDMT, leads to worsening outcomes in women. @lesleejshaw #SCCT2021
Women’s CVD risk can be underestimated. Female specific risk enhancers help. #CAC if risk uncertain. Women have lower #CAC prevalence than men but prevalence increases after menopause. CAC when present confers greater risk of incident CVD in women than men. @lesleejshaw #SCCT2021
Prevalence of non-obstructive #CAD is higher in women but is prognostic of risk. @lesleejshaw #SCCT2021
1/ Hot-off-the-press 🔥✍🏽🗣
Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors
#PrecisionCardioOnc @SpringerNature
Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio
rdcu.be/b3q0Y
Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors
#PrecisionCardioOnc @SpringerNature
Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio
rdcu.be/b3q0Y
2/ 🔥✍🏽🗣
A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs
Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias
#CardioOnc
A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs
Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias
#CardioOnc
3/ 🔥✍🏽🗣
An eminent need is optimal risk management, surveillance, detection, and prevention
The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts
#cvPrev #PrevCardioOnc #CardioOnc
An eminent need is optimal risk management, surveillance, detection, and prevention
The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts
#cvPrev #PrevCardioOnc #CardioOnc
1/ Hot-off-the-press!
Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts
ahajournals.org/doi/10.1161/JA…
#CardioOnc #CardioOncology #PrevCardioOnc
@avolgman @AnaBaracCardio @DrTochiCardiOnc
Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts
ahajournals.org/doi/10.1161/JA…
#CardioOnc #CardioOncology #PrevCardioOnc
@avolgman @AnaBaracCardio @DrTochiCardiOnc
2/ Approx 4 million American 👩🏽👩🦳 are currently living with a hx of invasive breast ca, w/ 270,000 diagnosed within the past year. Among these 👩🏽👩🦳, 64% are aged ≥65 years. Among older 👩🏽👩🦳 survivors of breast cancer, cardiovascular disease (#CVD) is the leading cause of death
3/ Are ACEIs and β‐blockers indicated and efficacious for everyone with breast cancer? Should we offer these medications prophylactically to all patients planned for chemotherapy, radiation, or targeted therapy? #CardioOnc #CardioOncology
1/ Preventive Cardio-Oncology Tutorial #PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”
tinyurl.com/PrevCardioOncT…
“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”
tinyurl.com/PrevCardioOncT…
2/ “A myriad of novel cardiotoxic chemotherapeutic & immunotherapeutic drugs are continuously being developed in #Oncology, with diverse cardiovascular (CV) effects.”
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
3/ Chest radiation “can result in accelerated atherosclerosis, pericardial disease, valve disease, conduction abnormalities, & cardiomyopathies.”
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
(1/12) #JACC #Tweetorial: #cvCAD in Young Adults: A Hard Lesson, but a Good Teacher
✔️#AFIJI Cohort 20 year-follow-up: fal.cn/34s2J @ActionCoeur
✔️ Editorial: fal.cn/34s2K by @ErinMichos and @AChoiHeart
✔️#AFIJI Cohort 20 year-follow-up: fal.cn/34s2J @ActionCoeur
✔️ Editorial: fal.cn/34s2K by @ErinMichos and @AChoiHeart
@ActionCoeur @ErinMichos @AChoiHeart @MichelZedBay @mathieukerneis @docjohanne @DrHulot_PARCC (2/12) #JACC #Tweetorial: The consequences of premature #cvCAD are devastating. Declines in ASCVD events have not extended to younger adults and rates have increased particularly among women 35-54 yrs old.
Arora, et al @CircAHA: fal.cn/34s2N
Arora, et al @CircAHA: fal.cn/34s2N
@ActionCoeur @ErinMichos @AChoiHeart @MichelZedBay @mathieukerneis @docjohanne @DrHulot_PARCC @CircAHA (3/12) #JACC #Tweetorial: In this issue Collet, JP, et al (@ActionCoeur) describe a cohort of 880 adults who experienced symptomatic #cvCAD at a young age (<45 years) presenting as obstructive CAD followed for up to 20 years. fal.cn/34s3H
